649
Views
2
CrossRef citations to date
0
Altmetric
Mitogenome Announcement

Intraspecific variations among the chloroplast genomes of Artemisia scoparia (asteraceae) from Pakistan and China

, , , & ORCID Icon
Pages 3182-3184 | Received 04 Aug 2020, Accepted 11 Aug 2020, Published online: 18 Aug 2020
 

Abstract

Artemisia scoparia Waldst. et Kitam. is an important medicinal plant of Asteraceae. Inconsistent pharmacological activities have been reported for A. scoparia from China and South Asia. As the first step to understand the underlying genetic basis, we sequences the chloroplast genome for A. scoparia collected from China and compared with one collected from Pakistan. The circular chloroplast genome of A. scoparia is 151,008 bp long, which is slightly shorter than that of A. scoparia-Pakistan. It encodes 87 protein-coding genes, 8 ribosomal RNA genes, and 37 transfer RNAs. The overall GC content of the genome is 37.47%. Comparing with A. scoparia from China and Pakistan identified the inversion of the SSC region. Besides, a total of 79 single nucleotide polymorphisms and 39 insertions and deletions were identified. The results can be used to develop molecular markers to distinguish A. scoparia from different geographical areas that might have variable bioactivities.

Disclosure statement

No potential conflict of interest was reported by the author(s).

Data availability statement

The data that support the findings of this study are openly available in GenBank at https://www.ncbi.nlm.nih.gov/nuccore/MT830857. The voucher sample has been deposited in the Herbarium of Institute of Medicinal Plant Development in Beijing, China with the accession number: implad201910001.

Additional information

Funding

This work was supported by the Chinese Academy of Medical Sciences, the Innovation Funds for Medical Sciences (CIFMS) [2017-I2M-1-013, 2016-I2M-3-016]; the National Science Foundation Funds [81872966]; the National Science &Technology Fundamental Resources Investigation Program of China [2018FY100705]; and the National Mega-Project for Innovative Drugs of China [2019ZX09735-002]. The funders were not involved in the study design, data collection, and analysis, decision to publish, or manuscript preparation.